SCHEMBL2815752

SCHEMBL2815752

CCOc1cccc(-c2cnc3c(NC)nc4ccccc4n23)c1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 1/20 0.46
IKBKB O14920 8/20 0.46
CHUK O15111 5/20 0.46
MAPT P10636 3/20 0.44
KDM4E B2RXH2 2/20 0.41
TP53 P04637 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KMT2A Q03164 2/20 0.40
FYN P06241 1/20 0.40
RAB9A P51151 1/20 0.40
TOP2A P11388 1/20 0.39
FGFR1 P11362 1/20 0.38
FGFR2 P21802 1/20 0.38
FGFR3 P22607 1/20 0.38
THRB P10828 1/20 0.38
NR3C1 P04150 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30136943 0.89 IKBKB (0.47) HTR2CIKBKBCHUKMAPTKDM4E
SCHEMBL2817762 0.89 IKBKB (0.47) HTR2CIKBKBCHUKMAPTKDM4E
SCHEMBL2813932 0.88 MAPT (0.51) HTR2CIKBKBCHUKMAPTKDM4E
SCHEMBL2816936 0.87 IKBKB (0.51) IKBKBCHUKMAPTKMT2ATHRB
SCHEMBL2818431 0.85 ADORA2A (0.50) IKBKBCHUKMAPTTP53SMN1; SMN2
SCHEMBL2816677 0.83 HTR2C (0.51) HTR2CIKBKBCHUKMAPTKDM4E
SCHEMBL17895103 0.82 IKBKB (0.49) HTR2CIKBKBCHUKMAPTKDM4E
SCHEMBL2815174 0.82 IKBKB (0.48) HTR2CIKBKBCHUKMAPTKDM4E
SCHEMBL2816218 0.82 IKBKB (0.47) HTR2CIKBKBCHUKKDM4ESMN1; SMN2
SCHEMBL2815160 0.82 IKBKB (0.47) HTR2CIKBKBCHUKKDM4ETP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2205602-B1 IMIDAZO[1,2-A]QUINOXALINES AND DERIVATIVES THEREOF FOR TREATING CANCERS UNIV MONTPELLIER (FR) 2018-09-26 EP claimed
US-8378098-B2 Imidazol[1,2-α]quinoxalines and derivatives for the treatment of cancers UNIVERSITE DE MONTPELLIER I (FR) 2013-02-19 US claimed
EP-2205602-B1 IMIDAZO[1,2-A]QUINOXALINES AND DERIVATIVES THEREOF FOR TREATING CANCERS UNIV MONTPELLIER (FR) 2018-09-26 EP disclosed
US-8378098-B2 Imidazol[1,2-α]quinoxalines and derivatives for the treatment of cancers UNIVERSITE DE MONTPELLIER I (FR) 2013-02-19 US disclosed
US-20100249142-A1 IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS UNIVERSITE DE MONTPELLIER I 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249142-A1 IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS IDH3A, NRAS, KRAS HTR2C 1292/4885IKBKB 855/4885CHUK 409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.